Fortis Healthcare gets CCI nod to acquire additional 31.52 per cent stake in Agilus for Rs 1,780 crore
New Delhi: The Competition Commission of India has approved the acquisition of additional share capital of Agilus Diagnostics Limited (Agilus) by Fortis Healthcare Limited (FHL).
The Proposed Combination involves the acquisition of an additional 31.52% share capital of Agilus by FHL. Post the Proposed Combination, the shareholding of FHL in Agilus will increase from 57.68% to 89.2%.
FHL is primarily engaged in providing integrated healthcare delivery services such as medicare, healthcare, diagnostics and its businesses include managing and operating a network of multi-specialty hospitals and providing preventive healthcare and diagnostics services.
Also Read:Fortis Hospital performs total Knee Replacement Surgery on 97-year-old woman
The diagnostics services business of FHL is being undertaken primarily through Agilus.
Agilus is, inter alia, engaged in establishing, managing, maintaining clinical reference laboratories and other laboratories for providing testing and diagnostic services. It offers a range of routine and specialized diagnostics tests as well as wellness packages that cover an extensive range of specialties.
It also offers a wide range of corporate wellness services and preventive care health packages comprising several pathology and radiology tests including home collection services.
Detailed order of the Commission will follow.
Also Read:Fortis Healthcare to Raise Rs 1,500 Crore Through NCDs
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.